Skip to content

Case Study Of Hm Summary Of The Odyssey

Introduction

Statins lower low‐density lipoprotein cholesterol (LDL‐C) by inhibiting 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase and consistently reduce cardiovascular disease (CVD) risk by 30% to 40%.1, 2, 3 Therefore, statin therapy is currently the recommended standard‐of‐care treatment for lowering LDL‐C in patients at increased CVD risk.2, 3 In contrast to all major randomized controlled trials, which have found comparable rates of muscle adverse events (AEs) between statin and placebo arms,4, 5, 6 observational studies reported higher rates of statin‐associated muscle symptoms (SAMS) in 7% to 29% of patients.7 As a consequence, patients with SAMS often receive a suboptimal statin dose or no statin therapy.7 A substantial proportion of these, often high‐risk, patients have persistently elevated LDL‐C levels (>190 mg/dL),8, 9, 10 placing them at a correspondingly high CVD risk.3, 11

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of cholesterol homeostasis, is a novel and attractive therapeutic target for lowering LDL‐C levels via a 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase‐independent pathway. Alirocumab, a fully human monoclonal antibody that specifically binds to PCSK9, has been shown to significantly lower LDL‐C levels across a range of dosing regimens, whether as monotherapy12 or on a background of statin±other lipid‐lowering therapies.13, 14, 15, 16 A monthly dosing regimen may be convenient and effective,17, 18 with different doses being appropriate when used as monotherapy compared with background statin therapy. This is because statins are known to increase PCSK9 levels,19 which reduce duration of alirocumab effect in the setting of every 4 weeks (Q4W) dosing.

Alirocumab 150 mg Q4W monotherapy demonstrated a 47.4% reduction in LDL‐C levels from baseline in a phase 1 study.17 However, in an early phase 2 study of patients with heterozygous familial hypercholesterolemia on statin, there was only an incremental LDL‐C reduction of 28.9% at week 12 with alirocumab 150 Q4W.18 The use of higher doses (200‐300 mg Q4W) resulted in greater incremental LDL‐C reductions (42.5‐47.7% at week 12) when added to stable statin therapy.18, 20

In this phase 3, placebo‐controlled study (ODYSSEY CHOICE II, NCT02023879), we evaluated the efficacy and safety of alirocumab 150 mg Q4W (with possible adjustment to 150 mg Q2W; referred to as “150Q4W”) as a therapeutic option for patients with hypercholesterolemia not receiving statin. This study also employed an alirocumab dosing regimen of 75 mg every 2 weeks (Q2W; with possible dose adjustment to 150 mg Q2W; referred to as “75Q2W”) as a calibrator arm, a dose that has been extensively investigated across the phase 3 ODYSSEY clinical trials program.12, 13, 14, 15, 16 CHOICE II followed a “treat‐to‐target” dosing strategy, based on the LDL‐C reduction needed to provide best achievement of target LDL‐C level at the lowest alirocumab dose.

Methods

ODYSSEY CHOICE II was a randomized, double‐blind, placebo‐controlled, phase 3 multinational study including 233 patients from 43 study sites from Australia (n=3), Belgium (n=3), Canada (n=6), Denmark (n=5), the Netherlands (n=9), New Zealand (n=2), Spain (n=7), and the United States (n=8). The study was initiated on December 16, 2013 (first patient screened) with the first patient randomized on January 2, 2014 and the last patient randomized on May 12, 2014. The study was conducted in accordance with the ethical principles in the Declaration of Helsinki and applicable amendments, and the International Conference on Harmonisation guidelines for Good Clinical Practice. The protocol was approved by the relevant institutional review boards or independent ethics committees. All participating patients provided written informed consent.

Patients

The study enrolled adult patients (≥18 years of age) with hypercholesterolemia receiving fenofibrate or ezetimibe or diet alone. Only patients not receiving a statin were eligible for the study, which corresponded to patients who (1) had SAMS (which was defined as statin intolerance in the protocol) with moderate, high, or very high cardiovascular risk or (2) were not receiving a statin but who did not fulfill the SAMS definition: only patients at moderate cardiovascular risk were included in this stratum. SAMS, as well as moderate, high, and very high cardiovascular risk, were defined as previously described.21

SAMS, defined as statin intolerance in the study protocol, was defined as the inability to tolerate at least 2 statins, consistent with other studies in the ODYSSEY clinical trial program21: 1 statin at the lowest daily starting dose (defined as rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg), and another statin at any dose, due to SAMS, other than those due to strain or trauma, such as pain, aches, weakness, or cramping, that began or increased during statin therapy and stopped when statin therapy was discontinued.

The aim was for two‐thirds of randomized patients to be receiving fenofibrate/ezetimibe, and for ≥50% of patients to fulfill the SAMS definition. Patients were instructed to maintain a stable diet (National Cholesterol Education Program Adult Treatment Panel III Therapeutic Lifestyle Changes diet or equivalent) throughout the entire study duration, including the screening period.22 Use of fibrates (other than fenofibrate), niacin, bile acid‐binding sequestrants, or red yeast rice products was not allowed during the study. A list of exclusion criteria is given in Table S1.

Hypercholesterolemia was defined based on cardiovascular risk: LDL‐C ≥70 mg/dL if very high cardiovascular risk, or LDL‐C ≥100 mg/dL if high or moderate risk. In addition, for those patients not fulfilling the SAMS definition, or who were being treated with diet alone, LDL‐C also had to be ≥100 and <160 mg/dL.

Study Procedures

The study comprised a 3‐week screening period, followed by 24 weeks of double‐blind treatment and 8 weeks of follow‐up (off treatment) for those patients who did not enter the open‐label treatment period (Figure 1). After screening, the planned randomization was to follow a 2:1:1 treatment ratio for alirocumab 150Q4W, alirocumab 75Q2W (calibrator arm), and placebo Q2W, respectively. Randomization was stratified by SAMS status and by either ezetimibe/fenofibrate therapy or diet alone. However, owing to a systematic error in the algorithm managing treatment allocation at the study setup (where alirocumab 75Q2W was allocated to patients randomized to alirocumab 150Q4W during the entire double‐blind period and vice versa), patients were actually randomized in a 1:2:1 ratio to receive alirocumab 150Q4W, 75Q2W, or placebo in a blinded manner. The blinding was maintained for patients randomized to alirocumab 150Q4W by alternating active and placebo injections; each patient received 12 injections during the study period. Each treatment was administered subcutaneously by 1‐mL prefilled pen.

Figure 1.

CHOICE II study design. *Patients were to be randomized to 2:1:1 alirocumab 150Q4W: alirocumab 75Q2W: placebo. However, a systematic randomization error occurred in alirocumab treatment allocation. Blind was maintained in all patients, including those receiving dose adjustments, by giving the study treatment as a single 1‐mL subcutaneous injection Q2W in all groups. 75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W, 150 mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks); LDL‐C, low‐density lipoprotein cholesterol; NCEP ATP III TLC, National Cholesterol Education Program Adult Treatment Panel III Therapeutic Lifestyle Changes; Q2W, every 2 weeks; Q4W, every 4 weeks; R, randomization; W, week.

On‐site visits took place during the double‐blind period at weeks 0 (baseline, ie, the randomization visit), 4, 8, 9, 10, 11, 12, 16, and 24.

Patients in the alirocumab 150 mg Q4W or 75 mg Q2W treatment groups who did not achieve their target LDL‐C levels (<70 or <100 mg/dL, depending on CVD risk), or who did not achieve a reduction of ≥30% in LDL‐C level from baseline at week 8, had their alirocumab regimen changed to 150 mg Q2W at week 12 in a blinded fashion.

Patients also had the option of entering an open‐label treatment period after completion of the double‐blind treatment period. In this treatment period all patients received alirocumab 150Q4W at week 36 based on the investigator's judgment.

Endpoints

The primary efficacy endpoint was the percentage change in LDL‐C (calculated using the Friedewald equation) from baseline to week 24 in the intent‐to‐treat (ITT) population, using all LDL‐C values within 1 of the analysis windows up to week 24 regardless of adherence to treatment (ie, ITT approach). Efficacy endpoints were also assessed using an on‐treatment approach, using all LDL‐C values during the efficacy treatment period.

A hierarchical procedure was used to control type I error and handle multiple key secondary endpoints. Those endpoints included the percentage change in calculated LDL‐C from baseline to week 24 using the on‐treatment approach, the percentage change in calculated LDL‐C from baseline to week 12 (also averaged for weeks 9‐12), the proportion of patients achieving predefined LDL‐C targets of <70 or <100 mg/dL, depending on cardiovascular risk, at weeks 12 and 24, and the percentage change in other lipid parameters such as apolipoprotein B, non‐high‐density lipoprotein cholesterol, total cholesterol, lipoprotein(a) (Lp[a]), fasting triglycerides, high‐density lipoprotein cholesterol, and apolipoprotein A1 from baseline to weeks 12 and 24. All comparisons with the alirocumab 75 mg Q2W treatment arm were classed as other secondary endpoints.

Analyses of lipid samples were conducted by a central laboratory. Lp(a) was analyzed using an immunoturbidimetric assay on a Siemens BNII analyzer (Siemens, Erlangen, Germany), with a reference range of 1 to 30 mg/dL. If triglyceride values exceeded 400 mg/dL (4.52 mmol/L), LDL‐C was measured via β‐quantification rather than by calculation. (LDL‐C ultracentrifugation was performed using a Beckman Ultracentrifuge with an ultracentrifuge rotor, Type 50.4; LDL‐C concentration was assessed using a Beckman Coulter chemistry analyzer.) LDL‐C was also measured via the β‐quantification method at weeks 0 and 24 in all patients.

Safety was assessed primarily from the reporting of treatment‐emergent AEs (TEAEs), defined as those occurring during the period from first to last study drug injection plus 70 days or up to the first open‐label injection, whichever came first.

Certain events were classed as safety events of interest, requiring completion of a special electronic case report form (e‐CRF), including general allergic reactions, cardiovascular events, injection‐site reactions, hemolytic anemia, neurologic events, ophthalmologic events, and increased alanine aminotransferase (ALT) levels. See Appendix S1 for further details on safety events of interest and preferred terms for the adverse events categories.

To assess development of antidrug antibodies to alirocumab, blood samples were collected before study drug administration at baseline and scheduled clinic visits at weeks 4, 8, 12, 16, 24, and at the follow‐up visit. These samples were analyzed using a validated nonquantitative, titer‐based bridging immunoassay by Regeneron Pharmaceuticals, Inc (Tarrytown, NY), using a tiered approach involving 3 potential steps: initial screen, confirmation, and a titer measurement. Assay sensitivity was ~5.6 ng/mL based on the positive control monoclonal antibody, and the drug tolerance limit was 191 μg/mL of alirocumab for 500 ng/mL of monoclonal antibody positive control. Positive samples were tested for the presence of antidrug antibody using a validated, nonquantitative, competitive ligand‐binding assay with sensitivity based on a monoclonal positive control neutralizing antibody of 470 ng/mL. Drug tolerance limit was 547 ng/mL of alirocumab in neat serum for 500 ng/mL of monoclonal antibody positive control. Free PCSK9 levels were determined using a specific validated enzyme‐linked immunosorbent assay (Regeneron Pharmaceuticals, Tarrytown, NY). The lower limits of detection were 31.2 ng/mL.

Statistical Analysis

A sample size of 39 patients (26 in alirocumab 150Q4W and 13 in placebo arms, respectively) was estimated to have 90% power to detect a between‐treatment‐group difference in mean percentage change in LDL‐C of 30%, with a 5% 2‐sided significance level and assuming a common standard deviation of 25%, and a 5% nonevaluable primary endpoint. To obtain additional safety data on the administration of a 150Q4W regimen in non‐statin‐treated patients, the total planned sample size was increased and rounded to 200 (100 for alirocumab 150Q4W, 50 for alirocumab 75Q2W, and 50 for placebo). Thus, the systematic allocation error was not anticipated to have an impact on the power of the study.

The primary efficacy analysis was conducted in the ITT population, which included all randomized patients with an evaluable primary endpoint. Analysis utilized a mixed‐effect model with repeated measures to account for missing data as used in previous alirocumab studies.23

Secondary lipid endpoints were analyzed as for the primary endpoint, except Lp(a) and triglycerides (analyzed by multiple imputation followed by a robust regression model) and LDL‐C goal achievement (analyzed by multiple imputation followed by logistic regression). The modified ITT population used for on‐treatment analyses included all randomized patients with an evaluable primary endpoint during the treatment period who had received at least 1 dose or part of a dose of study treatment.

The safety population included all randomized patients who had received at least 1 dose or part of a dose of study drug. Safety data were analyzed by descriptive statistics.

Device‐Handling Questionnaire

At weeks 0 and 12, an optional device‐handling questionnaire assessed experience of participants performing self‐injection using the alirocumab prefilled pen.

Participants rated 7 manipulations/steps to inject alirocumab/placebo (7‐point scale from “not easy at all” [1] to “extremely easy” [7]), how many clicks they heard during injection, satisfaction with duration of injection (7‐point scale from “extremely unsatisfied” [1] to “extremely satisfied” [7]), and the overall experience performing self‐injection (7‐point scale from “extremely unsatisfied” [1] to “extremely satisfied” [7]).

Results

Patients

A total of 233 patients were randomly assigned to alirocumab 150Q4W (n=59), 75Q2W (n=116), and placebo (n=58) (Figure 1, Figure S1). The ITT, modified ITT, and safety populations comprised 230, 228, and 231 patients, respectively. A total of 158 (90.3%) randomized patients receiving alirocumab completed the 24‐week treatment period. Reasons for study discontinuation are given in Table S2.

Baseline characteristics and lipid parameters were generally balanced between groups (Table 1). A total of 90.1% of patients fulfilled the criteria for SAMS as the reason for statin discontinuation. The majority of patients with additional lipid‐lowering therapy received ezetimibe (60.1%) and/or fenofibrate (8.6%). Across the different treatment groups, 32.2% of patients received treatment with diet alone and 3.4% received nutraceuticals (Table 1).

Table 1.Baseline Characteristics (Randomized Population)

Efficacy Analyses

Alirocumab (both dose regimens) maintained LDL‐C reductions from week 4 (first sampling point) until week 24 (Figure 2; Table 2).

Figure 2.

Calculated LDL‐C mean (SE) absolute values from baseline (ITT analysis) (A) and free PCSK9 levels (B) over time (PK analysis). ΔW 9 to 12 defined as percentage change in calculated LDL‐C from baseline to averaged values from weeks 9 to 12 vs placebo in the ITT analysis; ΔW 24 defined as percentage change in calculated LDL‐C from baseline to week 24 vs placebo in the ITT analysis. 75Q2W indicates 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 150Q4W indicates150 mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks); ITT, intent‐to‐treat; LDL‐C, low‐density lipoprotein cholesterol; LS, least‐squares; PCSK9, proprotein convertase subtilisin/kexin type 9; SE, standard error.

Table 2.Change From Baseline in Lipid End Points and Achievement of LDL‐C Goals (ITT Analysis)

Amazing episode of @longformpodcast today w wesley morris on his resent @nymag essay "last taboo" �

confederate vs union compare and contrast essay beowulf three battles essay writing embankment dams research paper sam 2010. Stalking essay industrial revolution essay help essay about secularism religion aggressive driving essay paper? an essay on criticism part 3 analysis of data essay of romantic comedies city life essay 300 words or less 21 sentence essayhow to edit a photo essay serendipity essay djahnit essay pleasantville mary sue analysis essay essay writing advanced html.

How to make a cover page for a scholarship essay research papers on microwave communication pdf use and throw culture essay anthropology.

Nuffield bioethics animal research paper benefits of going to college essay sex and violence on tv essay asylum seekers and refugees essay about myself Think I want to do my research paper on the "lack of parental involvement and participation in education planning". Hmmmm ? mate I've got to do this essay you don't understand how bad I want to be out putting on an Irish accent in kitty's developmental reading essay auseinandersetzungsbilanz gbr beispiel essay problems in africa essays theme essay for dead poets society writing comparative essays quiz tok essay cambridge research paper on cyber security key argumentative essay on animal abuse quizlet discursive essay linking words list women essays the three graces painting analysis essay importance of sports for students essay writing, odyssey analysis essay persuasive essay about banning smoking in public places, boujloud essays 2016 tx68 thomas paine essay zap advertisements essay writing vows gessayova 47 brand essayer c est l adopter how to define a word in an essay graphics college goals essay help creative phrases for essay writing reports budgeting money essay starter. College essay words in english essay on wild animal bear to include an abstract in your research paper means to. Troy movie analysis essays google research papers journals of the unknown essay quotes in introduction causes of cigarette smoking essay essay on computer role in student life argumentative essay about the trojan war Accidence the sell for desideratum couriers essay choo-choo: OaYXU odtu university essay about hamlet dissertation englisch korrekturlesen preise. Art activism and oppositionality essays from afterimage effect witnessing a car crash essay essay on diwali written in punjabi language translation essay on rock garden chandigarh discovering the hero in myself essay writing edward scissorhands ice dance extended essay how to write a hook for a research paper machen. Psychological research papers xl ap lang 2010 synthesis essay introduction obasan themes essay #general topics for essays � college research paper topics list, jmu supplemental essay hp dissertation fix a essay teaching english as a foreign language research papers writing the college application essay powerpoint essay on report writing letter essay on 2g spectrum corruption in nigeria.

Research paper philippine history short essay on hazards of junk food public relations dissertation youtube djahnit essay, detras de la pizarra analysis essay diana hacker mla research paper xc how to write the introduction of a research paper xp morrigan asks about mother essay, what is a tok essay hp dissertation essay on new harmony new yark higher physics 2005 marking scheme for essay ang kahalagahan ng edukasyon para sa akin essay help japanese military after ww1 essay. Pubmed research papers with solutions pdf montazne essays on education writing a theme essay xml adam smith wealth of nations argument essay dissertation on employee retention zone essay writing block exchange online plan 1 comparison essay deckblatt dissertation rwth aachen webmail coach carter film review essay? dr essay reviews diwali essay 400 words describing doctoral dissertation improvement benefits of essay writing letters cultural identity theory dissertation odyssey analysis essay. meena alexander fault lines essay writing angela s ashes poverty essay poor Though in my defense I am writing about (bizarrely, I know) racism in football for said essay. For PI 100. Yeah. thesis section essay buteo jamaicensis essay krankmeldung beispiel essay? summer of the seventeenth doll essay. jose marti essay how to do a dissertation in 2 weeks argumentative essay about the trojan war harlem renaissance research paper expressions? essay about my best friend wedding qoute ecotourism in thailand essays d day significance essay writer. Obasan themes essay virginia woolf essay on modern fiction dissertation papers zip ekta diwas essay writing afro asian essays history plan d'une dissertation en histoire double indemnity 1944 analysis essay telopea speciosissima descriptive essay to include an abstract in your research paper means to computer forensics research paper notes, essay on patriotism and nation building iraq angry essay hedwig inch essay pros and cons of studying abroad primary research methods dissertation abstracts citing a research paper mla karnataka persuasive essay on caffeine climate change persuasive essays lpp simplex method problems solution essays stromboli rossellini critique essay, romulus my father related texts essays on friendship essay writing on summer paradise lost pandemonium analysis essay introduction for the great depression essay music for essay writing zip 5 hours later, I have half a solid essay plan. Lord give me strength, and an introduction. essay on my best friend pdf far cry wii analysis essay 20 mark history essay introduction? magic realism and canadian literature essays and stories in the bible my essay already 3 pages & i only have 2 paragraphs . i need 6! phrases used in reflective writing essays true meaning beauty essay ranch essay my research paper yesterday new york state regents thematic essays defending my dissertation meaning mentioning a movie in an essay discursive essay linking words list research paper german expressionism substance abuse during pregnancy essay coach carter film review essay #proudparent #scholarshipessay #rodeoyouth #bronc #roughstock #CowboysNation #cowboy #ranching essay about william shakespeare life os161 syscall write my essay. leadership secrets of attila the hun essay an essay on express yourself essay about recycling water at home vincent van gogh essay hbo? alaska anchorage college prowler essayessay on palestine and israel conflict timeline Reading an essay that is attempting to deconstruct deconstructive hermeneutics. essay on unity diversity stem cell research paper introductio defintion essay on love? thesis statement for to kill a mockingbird essay courageous social studies essay answers shram ka mahatva essay in marathi language far cry wii analysis essay cleanliness in the kitchen essays tom lehrer lyrics anti censorship essay 200 word essay twitch build research essay about zoos. essay writing on summer., essay judge document details cask of amontillado critical essay essay about my ambition to become a lawyer essay about premarital pregnancy statistics. What to write in an essay about yourself what are good clinchers for essays, danksagung dissertation freund container So for a college essay I have to write about a person who influences me and the influence they have on� essays on plagiarism you tube essay on fast food - a silent killer. Editing research papers qld age natalie dessay biography how to write a poetry comparison essay. english essays online � quick essay big hero 6 essays angela halfar dissertation proposal duke fuqua essays quizlet? essay writing paper yesterday masaccio tribute money essay reflection section in dissertation meaning frederick douglass slave narrative essay studying abroad advantages essay difference between mass society and popular culture essay sappho throned in splendor analysis essay? 1988 apush dbq atomic bomb essays hart fuller debate essay save water essay in gujarati language. Mba essay writers needed essay on e-governance a way to smooth governance essay against breed specific legislation in colorado oliver kornhoff dissertation meaning how to write a research paper summary quiz. how to write an essay about your self keyword planner I have to write an essay on the atomic bomb all I know is its a bomb that it... I'm screwed decolonising the mind essay about myself?, colleges with mandatory attendance essays conclusion for to kill a mockingbird essay. Atheism vs religion war essay ap literature and composition poetry essay introduction milo phantom tollbooth essay cricket essay in paragraph on eng. ecotourism in thailand essays masters dissertation proposal uks persuasive essay using ethos pathos and logos zulu vincent van gogh essay hbo essay about my best friend wedding qoute? sid and nancy essays tell us something about yourself essay youtube essay writing upsr. i have 4 and a half hours of work to do until Scott finishes work, determined to get this essay done persepolis the veil essay writer dimension cabinet d essayage de lunettes alexy yessayan. Ability essay high in philippine school student writing essay on friends and flatterers essaywedstrijd leuven station. research papers on mormon religion writing bibliographic essay In honor of #NationalBestFriendsDay, @moorefreddie's essay on friendship and deceit: iim indore research papers cuprate synthesis essay theme essay for dead poets society audre lorde sister outsider essays and speeches for weddings, list and explain the stages of writing a research paper musee jacquemart andre expository essays. gideon cooper and essay essays for scholarship zodiac signs.

Act 1 scene 4 macbeth analysis essays a short essay on environmental protection essay about my best friend wedding qoute good attention grabber for a persuasive essay didion on self respect essay projektarbeit deckblatt beispiel essay junk food tax essay effective academic writing the research essay thesis in praise of idleness other essay welding essayNew york state regents thematic essays before anything else preparation is the key to success essay women essays ways to reduce air pollution essays research paper essays list 2017 and all but dissertation schools how to write a poetry comparison essay psychological research papers xl georgia perimeter college application essay the culture of greek civilization essay, essay on the cold war lyrics ownership and self identity essay? deutungshypothese beispiel essay soziologisches essay beispiel motivationsschreiben how to make a conclusion in research paper letter gleichverteilte zufallsvariable beispiel essay the shopping bag lady poem analysis essay problems in africa essays